Eli Lilly Reports Results of Taltz (ixekizumab) in Head-to-Head P-IV IXORA-R Study for Moderate to Severe Plaque Psoriasis

 Eli Lilly Reports Results of Taltz (ixekizumab) in Head-to-Head P-IV IXORA-R Study for Moderate to Severe Plaque Psoriasis

Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext to Develop Therapies for Autoimmune Disorders

Shots:

  • The P-IV IXORA-R study involves assessing of Taltz vs Tremfya (guselkumab) in 1,027 patients with moderate to severe plaque psoriasis for a total of 24 wks., with the primary analysis conducted at 12 wks.
  • The P-IV IXORA-R study results: met its 1EPs & 2EPs i.e, complete skin clearance as measured by PASI 100 @12wks. (41.3% vs 24.9%) & superior to Tremfya in achieving PASI 75 @2wk., PASI 90 @4 & 8 wks., PASI 100 @4, 8 & 24wks., sPGA 0 @12wk. and PASI 50 @1wk. respectively
  • Taltz is mAb targeting IL-17A cytokine and inhibits its interaction with the IL-17 receptor, thus inhibiting pro-inflammatory cytokines and chemokines while Tremfya is a mAb targeting p19 subunit of IL-23 and has received the FDA’s approval for mod. to sev. plaque psoriasis in July’2017

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Behance

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post